Liquid Biopsy Market Size, Share and Trends 2026 to 2035

What is the Liquid Biospy Market Size?

The global liquid biopsy market size accounted for USD 7.05 billion in 2025 and is predicted to increase from USD 8.07 billion in 2026 to approximately USD 24.87 billion by 2035, representing a CAGR of 13.44% from 2026 to 2035. The liquid biopsy market is driven by the increasing incidence of cancer and the increasing demand for non-invasive diagnostic testing.

Market Highlights

• North America region has contributed 45.59% in 2025.
• By technology, the NGS segment hit revenue share of around 65.20% in 2025.
• By sample type, blood sample-based tests hit highest market share 67.59% in 2025.
• By usage, clinical segment has held revenue share of 72.17% in 2025.
• By biomaker, cell-free DNA segment has held revenue share of 47.87% in 2025.
• By product, kits & consumables has held revenue share of 53.12% in 2025.
• By indication, lung cancer has generated revenue share of 32.10% in 2025.
• By application, screening segment has accounted revenue share of 39.27% in 2025.
• By circulating biomarker, the cell-free DNA segment is anticipated to show considerable growth in the market over the forecast period.
• By products, the test/services segment held a significant share in 2024.

Market overview

The Silent Detective: How Liquid Biopsy Is Finding Cancer Early

The liquid biopsy market holds remarkable importance in modern healthcare because of its potential for early cancer detection, enhanced patient outcomes, and personalized treatment strategies. It provides a less invasive option to traditional tissue biopsies, permitting for repeated monitoring of disorder progression and even response to therapy. Liquid biopsies offer valuable insights into the genetic profile of a tumor, permitting oncologists to choose the most effective treatment for individual patients.

This personalized approach to cancer treatment reduces unnecessary treatments and even maximizes the chances of successful results. The market is anticipated to expand thus as liquid biopsies become more broadly adopted in clinical practice and even new applications are discovered. Researchers at the University of Chicago have studied and developed a more sensitive liquid biopsy test that uses RNA in place of DNA for detecting cancer.

How is AI enhancing the liquid biopsy industry?

AI is significantly improving the liquid biopsy industry by enhancing early cancer detection, disease monitoring, and even personalized treatment strategies. AI can integrate information from numerous sources, including proteomics, genomics, and imaging, to offer a more comprehensive view of the disorder, contributing to more accurate diagnoses. AI can predict treatment results and detect patients who are most likely to respond to specific therapies, permitting personalized treatment plans. AI-based liquid biopsies are crucial to understanding the promise of precision oncology, where treatments are monitored to the individual patient's specific genetic along with molecular profile.

Liquid Biopsy Market Trends

• Growing Adoption of Non-Invasive Cancer Diagnostics: Liquid biopsy is becoming an alternative to tissue biopsy, a less painful procedure with lower risk, and is more convenient for the patient, as it allows for earlier detection of cancer, monitoring, and assessing treatment.
• Advancements in Genomic and Sequencing Technologies: Evolution of next-generation sequencing, PCR techniques, and biomarker detection are making liquid biopsy testing more sensitive and more accurate, and pushing its rise in use in oncology and precision medicine.
• Expansion Beyond Oncology Applications: The primary use cases are for cancer diagnostics, but increased adoption applications such as prenatal testing, organ transplant management, and infectious disease identification are new areas of opportunity for market players.
• Rising Investments and Strategic Collaborations: Investments are growing among the liquid biopsy companies, and research institutes are establishing strategic relationships among themselves and other partners for product development, commercialisation, and regulatory clearance for liquid biopsy applications in global healthcare markets.

Liquid Biopsy Market Outlook

• Industry Growth Overview: The global liquid biopsy market is poised for substantial expansion between 2026 and 2035, driven by the rising global cancer burden, growing preference for non-invasive diagnostics, and the accelerating shift toward precision medicine. Liquid biopsy is in high demand for multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring applications, as clinicians and researchers increasingly prioritize early intervention and personalized treatment planning.
• Major Trend: One major trend in the market is the transition from traditional tissue biopsies to liquid-based assays that use simple blood samples. These non-invasive tests reduce patient risk, lower healthcare costs, and enable faster clinical decision-making. The integration of artificial intelligence (AI) and multi-omics platforms is further enhancing diagnostic accuracy, minimizing false positives, and enabling the detection of multiple cancer types in a single test. This combination of convenience, efficiency, and precision is reshaping how cancer is diagnosed and monitored.
• Global Expansion: Leading companies are broadening their reach into high-growth regions such as Asia-Pacific, Latin America, and Eastern Europe. Growth in APAC is driven by rising cancer rates and growing investments in healthcare infrastructure. Collaborations between local and international companies are essential for navigating regional regulations and meeting unique market needs.
• Major Investors: The liquid biopsy sector is attracting robust investment from venture capital firms and major diagnostics companies. Industry pioneers such as Guardant Health, Illumina, and Roche continue to lead through intensive R&D, acquisitions, and collaborations aimed at enhancing test accuracy and clinical adoption. Investors are drawn by the technology's potential to revolutionize oncology diagnostics, align with global precision medicine initiatives, and capture a significant share of the market.
• Startup Ecosystem: A growing startup ecosystem focuses on developing innovative technologies for early cancer detection and monitoring. Innovators are employing advanced methods like methylation profiling, fragmentomics, and AI to develop highly sensitive and accessible tests. Many are securing substantial VC funding to create scalable, next-generation sequencing-based solutions.

Market Scope

Market Dynamics

Drivers

Growing Prevalence of Cancer and Need for Early Identification

The global liquid biopsy industry is motivated by an increase in the cases of many types of cancer, such as lung, breast, colorectal, and prostate cancer. As the number of cancer cases in the world keeps increasing, there is a need to search for ways to find cancer earlier, so that it increases the chances of treatment and survival. The liquid biopsy can be non-invasive, highly effective as an alternative to conventional tissue biopsies, reliably allowing the early detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other cancer markers within the blood and other body fluids. As the world continues to focus on the development of sophisticated diagnostic tools and personalized cancer treatment, the liquid biopsies market is getting popular.

Restraint

High Expenses and Limited Reimbursement Guidelines

The liquid biopsy methods commonly involve the use of expensive technology sets, such as next-generation sequencing (NGS) and biomarker-detecting solutions, which are costly. Such costs reduce accessibility, especially in low- and middle-income countries whose healthcare budget is limited. The absence of clearly defined reimbursement parameters would raise concerns among healthcare professionals about suggesting a liquid biopsy. Absence of standardized pricing models as well as clinical validation of some cancer types also further hampers adoption. Besides, cost-cutting policies are of primary importance to the majority of healthcare systems, which may become an obstacle to the adoption of new, premium-priced diagnostic technologies.

Opportunity

Developments in Precision Medicine and Biomarker Technologies

The exploration of circulating tumor cells, circulating tumor DNA, and extracellular vesicles is enhancing the sensitivity, specificity, and clinical usefulness of liquid biopsy tests. Such innovations provide an opportunity to detect tumor-specific changes more precisely and monitor their response to treatment and progression in real-time. Accurate medicine utilizes these possibilities to personalize cancer treatment on the basis of a specific genetic make-up of a person, making it more efficient and causing fewer side effects. Due to the increasing focus on personalized oncology as one of the central factors in cancer care, pharmaceutical and diagnostic companies are putting their efforts into developing liquid biopsy technology to efficiently develop targeted treatments.

Segments Insights

Technology Insights

The NGS Segment Held the Largest Share of the Liquid Biopsy Market in 2025

The NGS segment held a dominant position in the liquid biopsy market in 2025, as it enables the detection of multiple genetic alterations in the tumour with high sensitivity and accuracy. NGS technology is helping to diagnose cancer at a very early stage, choose the best treatment for the disease, and monitor it. There's a growing demand for advanced sequencing technologies due to the use of precision medicine and targeted therapies.

Usage Insights

The Clinical Segment Dominated the Liquid Biopsy Market in 2025

The clinical segment dominated the liquid biopsy market in 2025 because of the increasing usage of liquid biopsy tests in the healthcare routine. It is less invasive than the normal tissue biopsy; health care providers are increasingly relying on liquid biopsy as a diagnostic, selection for treatment, monitoring, and detection of recurrence tool, particularly for cancer. The use of liquid biopsy has been integrated into the clinical workflow, with the rise in cancer prevalence and the importance of precision medicine.

Types of Sample Insights

The Blood Segment Dominated the Liquid Biopsy Market in 2025

The blood segment dominated the market in 2025, due to easy collection, low invasiveness, and wide clinical applications. Liquid biopsies of blood can detect and quantify circulating tumour cells, circulating tumour DNA, and other biomarkers. It was easy and frequent to get blood that was suitable for disease monitoring, treatment evaluation, and early diagnosis of cancer.

Indication Type Insights

The Lung Cancer Segment Dominated the Liquid Biopsy Market in 2025

The lung cancer segment dominated the liquid biopsy market in 2025, with the high prevalence of the cancer disease in the world and the need for early and precise diagnosis. Liquid biopsy has become relevant in the detection of genetic alterations associated with lung cancer, as well as for monitoring the disease via liquid analysis. In lung cancer patients, liquid biopsies might be a more convenient alternative to tissue biopsies.

Biomarker Insights

The cell-free DNA segment dominated the liquid biopsy market in 2025 and is expected to continue its growth trajectory in the coming years. The segment's growth is attributed to the rising demand for cfDNA kits due to easier isolation of cfDNA in the bloodstream, owing to early detection of cancer by liquid biopsy tests. It aims to identify DNA fragments circulating in the bloodstream that have been released from tumor cells. This is a rapidly expanding area because of its potential for early cancer detection and monitoring treatment response. Innovations in NGS along with AI are thus driving its growth. Moreover, the concept of genetic testing based on cfDNA is gaining popularity due to its usefulness across most cancer types and is being integrated into standard clinical practices.

Circulating Biomarker Insights

The Circulating Tumour Cells Segment Dominated the Liquid Biopsy Market in 2025

The circulating tumour cells segment dominated the liquid biopsy market in 2025, as the presence of these cells plays a crucial role in diagnosing, prognosis, and monitoring cancer treatments. Cancer cells that have detached from the primary tumour and spread into the bloodstream to other parts of the body, which can be used to give information about the progression of the disease and its ability to spread.

Products Insights

The Kits and Consumables Segment Dominated the Liquid Biopsy Market in 2025

The kits and consumables segment dominated the market in 2025, due to the rise in the use of the Liquid Biopsy test in clinical and research settings. Kits and consumables are required items needed for sampling, sample preparation, extraction of the biomarkers, and molecular analysis. The growing use of liquid biopsy technologies for cancer diagnostics and precision medicine has driven up the demand for these products.

The kits and consumable segment is the fastest growing in the liquid biopsy market during the forecast period. The rising adoption of liquid biopsy for cancer screening, therapy selection, as well as recurrence monitoring, along with the growth of precision oncology, is driving the need for these kits and consumables.

Clinical Application Insights

The Diagnosis and Screening Segment Dominated the Liquid Biopsy Market in 2025

The diagnosis and screening segment dominated the liquid biopsy market in 2025, driven by growing emphasis on early cancer detection and preventive healthcare. Liquid biopsy is a non-invasive technique that can be used to identify cancer markers in liquids like blood and other body fluids. The use of these tests is growing in their adoption by healthcare providers, as a means to aid cancer screening programmes and decrease the need for invasive diagnostic testing.

The treatment selection segment is expected to grow the fastest in the coming years. This is mainly because it enables personalized medicine by identifying specific genetic mutations driving a patient's cancer, overcoming the limitations of invasive and sometimes unfeasible tissue biopsies, and facilitating dynamic, real-time monitoring of treatment resistance. Liquid biopsies offer a less invasive, quicker method for collecting critical genetic information necessary to guide treatment decisions for individual patients by supporting targeted therapy development.

Regional Insights

North America will lead the Global Liquid Biopsy Market in 2025

North America dominated the global liquid biopsy market in 2025 as the use of advanced cancer diagnostics is on the rise, and leading biotechnology companies in the region are. The area has well-developed health care facilities and good reimbursement policies, with increasing research and development investments. The rising number of liquid biopsy technologies being used for diagnosis, alongside their increasing acceptance in the clinical setting, is also driving market expansion.

U.S. Market Trends

The U.S. represents a large market for Liquid Biopsy with a high emphasis on early disease detection, and precision medicine is being embraced. In the field of cancer diagnosis, treatment monitoring, and detection of cancer recurrence, liquid biopsy technologies are gaining ground. Larger diagnostic companies, key investments in genomics research, and rising clinical applications of genomics are continuing to fuel the market growth.

U.S. Liquid Biopsy Market Size and Growth 2026 to 2035

The U.S. liquid biopsy market size was estimated at USD 2.40 billion in 2025 and is expected to hit around USD 7.96 billion by 2035 with a CAGR of 12.74% from 2026 to 2035.

Asia Pacific is Undergoing the Fastest Growth in the Liquid Biopsy Market

Asia Pacific is expected to grow at the fastest rate in the liquid biopsy market, attributed to the increasing number of patients, rising healthcare facilities, and increasing uptake of advanced diagnostic technologies. The growing government support for precision medicine, growing interest in early cancer diagnosis, and growing investments in precision medicine contribute to the market growth. Efforts to strengthen molecular diagnostics and access to new cancer screening solutions are underway in all countries in the region.

China Market Trends

China's liquid biopsy market is anticipated to grow significantly because of extensive awareness about healthcare and government regulations to promote the use of sophisticated diagnostics. Cancer is becoming more prevalent, and the shift towards precision oncology and strong investment in biotechnology research will keep the market growing. The country is making good strides in capacity building to expand genomic testing and promote innovation in molecular diagnostics.

Japan Liquid Biopsy Market Trends

The Japanese liquid biopsy market is expected to grow at a rapid CAGR over the forecast period, backed by governmental efforts and research-oriented investment to fight the increasing cancer cases. Grants have been offered to institutions and companies in the country to hasten the development and implementation of liquid biopsy instruments. As the population of Japan gets older and the number of people with cancer remains a problem, it is increasingly necessary to have early and precise means of diagnostics. The government support of personalized medicine, as well as the improvement of the public-private partnership, is likely to reinforce the presence of Japan in the Asia Pacific liquid biopsy market further.

Advancements in the Liquid Biopsy Market in Europe

Europe is expected to witness significant market growth throughout the forecast period, driven by increasing investment in cancer research, increasing adoption of molecular diagnostics, and rising demand for personalised medicine. Healthcare systems across the region are implementing advanced diagnostic technologies, such as early cancer detection systems and precision diagnostic tools. Supportive regulatory environment, extensive clinical studies, and increasing awareness of non-invasive diagnostic methods are helping to shape the market.

Germany Market Trends

Germany represents a major market for Liquid Biopsy as a result of its sophisticated healthcare system, strong biotechnology industry, and a growing focus on precision oncology. The nation is making significant investments in genomic research and cutting-edge diagnostics to enhance cancer treatment. Growing adoption of molecular testing, high cost of healthcare, and disregard for medical innovation are driving the molecular testing market.

UK Liquid Biopsy Market Trends

The UK liquid biopsy market is expected to increase at a large CAGR throughout the forecast period due to a well-developed healthcare system. A few pilot projects and trials are underway to justify the utilization of liquid biopsy in regular population screening. The joint efforts of universities, biotechnology companies, and government institutions are stimulating the production and marketing of the next-generation liquid biopsy technologies. Moreover, the UK government has paid attention to precision medicine and its financial climate of cancer research in the country, which contributes to innovation and the speed of product approvals.

Key Trends in the Liquid Biopsy Market in Latin America

Latin America is expected to witness significant growth in the liquid biopsy market due to the high burden of cancer, growing access to healthcare, and growing awareness of advanced diagnostic technologies. The government and health institutions are promoting cancer screening programs, and health facilities are being modernised to better meet the needs of patients. An upsurge in the demand for cost-effective and minimally invasive diagnostic solutions is projected to drive the market.

Brazil Market Trends

Brazil represents a significant market for Liquid Biopsy as the incidence of cancer is rising and the need for improved diagnostic solutions is also growing. Adoption is being fueled by rising investments in healthcare facilities, increased availability of molecular testing, and increased awareness of early detection of cancer. The volume of patients and the efforts to further improve oncology care add to market growth.

Growth of the Middle East and Africa in the Liquid Biopsy Market

The Middle East and Africa region is expected to witness significant growth in the liquid biopsy market owing to the increasing demand for innovative medical technologies and the modernisation of healthcare practices. The governments of the region are purchasing healthcare facilities and increasing access to specialised diagnostic services. Market development is being enhanced by raising awareness of the need for earlier detection of disease and by the rise in chronic diseases.

Saudi Arabia Market Trends

Saudi Arabia represents a significant market for Liquid Biopsy as the country continues to invest in healthcare transformation and cutting-edge diagnostics. The market is witnessing growth due to the rising awareness of cancer, increasing healthcare costs, and the increasing adoption of precision medicine. The government's agenda to boost the quality of healthcare and to make better new medical technologies available is driving the use of liquid biopsy tests.

Regulatory Landscape for the Liquid Biopsy Market

Value Chain Analysis

• R&D: The process consists of finding, developing, and validating blood biomarkers to ensure that cancer detection and monitoring are both accurate.
  Key players: Guardant Health, F. Hoffmann-La Roche Ltd
• Clinical Trials and Regulatory Approvals: A series of multi-phase testing for safety and efficacy, then regulatory authorities' approval for the drug's clinical use.
  Key players: IQVIA, CellMax Life, Natera
• Formulation and Final Dosage Preparation: The design of the diagnostic assays and preparation of the reagents that are needed for accurate laboratory testing of patient blood samples.
  Key players: Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific
• Packaging and Serialization: Test kits are packaged securely and carry traceable identifiers that allow for ensuring authenticity, quality control, and regulatory compliance.
  Key players: Thermo Fisher Scientific, Bio-Rad Laboratories
• Distribution to Hospitals, Pharmacies: Logistics management in such a way that diagnostic kits are delivered safely to laboratories and healthcare facilities under optimal conditions.
  Key players: Guardant Health, F. Hoffmann-La Roche Ltd
• Patient Support and Services: Providing instructions, technical support, and timely communication of accurate results to patients and healthcare providers.
  Key Players: Myriad Genetics, F. Hoffmann-La Roche Ltd

Competitive Landscape

The liquid biopsy market has key companies that are concentrating on launching technologies and developing precision oncology solutions and strategic partnerships for a competitive edge. Leading companies are working on cutting-edge cancer biomarker assays and platforms for Next Generation Sequencing to improve cancer diagnosis, monitoring of cancer treatment, and cancer detection and diagnostics capabilities. In April 2026, Precede Biosciences launched a genome-wide liquid biopsy platform to provide a deeper understanding of the functional biology of the tumour and applications in precision medicine of the future.

The steady R&D efforts, regulatory approvals, product launches, and marketing agreements to expand clinical usage and market presence all lead to competition. The liquid-biopsy-leading market is growing, with the cancer diagnostics market growing, and personalised medicine emerging as a significant application.

Top Companies in the Liquid Biopsy Market and their Offerings

• Guardant Health: Guardant Health offers advanced blood-based cancer diagnostics, including Guardant360 Liquid for comprehensive genomic profiling of advanced solid tumors and Guardant Reveal for minimal residual disease assessment and recurrence monitoring. They reported USD 739 million in revenue in 2024.
• F. Hoffmann-La Roche: Roche, through its subsidiary Foundation Medicine, provides liquid biopsy solutions such as the FoundationOneLiquid CDx comprehensive pan-tumor test and AVENIO ctDNA Analysis Kits. Their revenue in 2024 was USD 70.874 billion.
• Exact Sciences: Exact Sciences, a leader in cancer screening, offers the Cancerguard™ multi-cancer early detection blood test and Oncodetect™ for molecular residual disease and recurrence monitoring. Their reported revenue for 2024 is USD 2.759 billion.
• Illumina: Illumina provides the next-generation sequencing (NGS) platforms and tools used in many liquid biopsy applications. Their offerings include NGS solutions for detecting cancer biomarkers and the TruSight Oncology 500 ctDNA research panel. In 2024, their revenue was USD 4.37 billion.
• Bio-Rad Laboratories: Bio-Rad Laboratories is known for its digital PCR (ddPCR) technology and circulating tumor cell (CTC) analysis in the liquid biopsy market. Their offerings include Droplet Digital™ PCR systems for sensitive detection of biomarkers and the Genesis Cell Isolation System for CTC analysis. They reported USD2.567 billion in revenue for 2024.

Other Liquid Biopsy Market Companies

• Biocept Inc.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.

Recent Developments

• In April 2025, Labcorp reported adding two new products to its precision Oncology portfolio. The first one is Labcorp Plasma Detect, which was created as a clinical test, which was used as a method to determine the chances of patients with stage III colon cancer having the same illness again. The PGDx elio plasma focus Dx, the first and only FDA-cleared kitted liquid biopsy test in pan-solid tumors and assists in determining patients for targeted therapies. (Source : https://ir.labcorp.com)
• In January 2025, Tempus AI, Inc. claimed to launch the FDA-approved next-generation sequencing (NGS)-based in vitro diagnostic test, xT CDx. All ordering clinicians in the U.S. can order the test, which offers a full picture of genomic knowledge with one of the broadest and FDA-approved gene panels present in the market. (Source: https://in.marketscreener.com)
• In February 2024, Myriad Genetics, Inc. announced a partnership with the National Cancer Center Hospital East in Japan to start a SCRUM MONSTAR-SCREEN-3 study looking at the prognostic and predictive value of molecular residual disease testing. (Source: https://investor.myriad.com)

Segments Covered in the Report

By Technology

• NGS
• PCR
• FISH
• Other

By Usage

• RUO
• Clinical

By Types of Sample

• Blood
• Urine
• Saliva
• CerebroSpinal Fluid

By Circulating Biomarker

• Circulating Tumor Cells
• Cell-free DNA
• Circulating Cell-Free RNA
• Exosomes and Extracellular Vesicles
• Others

By Products

• Test/Services
• Kits and Consumable
• Instruments

By Indication Type

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Other cancers
• Non-Oncology Disorders

By Clinical Application

• Treatment Monitoring
• Prognosis and Recurrence Monitoring
• Treatment Selection
• Diagnosis and Screening

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa